Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 27, 2020 07:30 ET | Source: Metacrine, Inc.

Metacrine Presents Positive MET409 Phase 1b Clinical Data in NASH Patients at the Digital International Liver Congress™ 2020

SAN DIEGO, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on discovering and developing differentiated therapies to treat liver and...
August 25, 2020 07:30 ET | Source: Metacrine, Inc.

Metacrine Announces MET409 Receives FDA Fast Track Designation for the Treatment of NASH

SAN DIEGO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies to treat patients with liver...
June 09, 2020 07:30 ET | Source: Metacrine, Inc.

Metacrine Appoints Pharmaceutical Business and R&D Executive, Preston Klassen, M.D., MHS, as President and Chief Executive Officer

SAN DIEGO, June 09, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class drugs to treat patients with liver and...
November 18, 2019 07:30 ET | Source: Metacrine, Inc.

Metacrine to Present at Jefferies 2019 London Healthcare Conference

SAN DIEGO, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
September 18, 2019 07:30 ET | Source: Metacrine, Inc.

Metacrine Secures $50 Million Growth Capital Facility from K2 HealthVentures

SAN DIEGO, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
July 09, 2019 07:30 ET | Source: Metacrine, Inc.

Metacrine Doses First Patient in 12-Week NASH Proof-of-Concept Trial with a Sustained FXR Agonist

SAN DIEGO, July 09, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
July 02, 2019 07:30 ET | Source: Metacrine, Inc.

Metacrine to Present Initial Clinical NASH Data with Sustained FXR Agonist at Paris NASH Meeting 2019

SAN DIEGO, July 02, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
May 29, 2019 07:30 ET | Source: Metacrine, Inc.

Metacrine Reports Positive Interim Results with Sustained FXR Agonist in NASH Patients

SAN DIEGO, May 29, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
May 21, 2019 07:30 ET | Source: Metacrine, Inc.

Metacrine to Present at Jefferies 2019 Global Healthcare Conference

SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...
May 13, 2019 07:30 ET | Source: Metacrine, Inc.

Metacrine to Present Relevance of FXR and Specific FXR Drug Profiles for Possible Treatment of Inflammatory Bowel Disease at Digestive Disease Week 2019

SAN DIEGO, May 13, 2019 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biotechnology company focused on building an innovative pipeline of best-in-class drugs to treat liver and...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right